北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells
作者: Shi, Ruizan2,3,4; Li, Wei2,3,5; Zhang, Xiuli2,3; Zhang, Yanjun1,2,3; Peng, Hongwei2,3; Xie, Yinliang2,3; Fan, Dongmei2,3; Liu, Rong2,3; Liu, Xuyi6; Xiong, Dongsheng2,3
关键词: PHII-7 ; MDR (multidrug resistance) ; P-gp (P-glycoprotein) ; Reversal effect
刊名: EUROPEAN JOURNAL OF PHARMACOLOGY
发表日期: 2011-11-01
DOI: 10.1016/j.ejphar.2011.07.047
卷: 669, 期:1-3, 页:38-44
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: MEDIATED MULTIDRUG-RESISTANCE ; MULTIPLE-DRUG RESISTANCE ; LEUKEMIA-CELLS ; APOPTOSIS ; MECHANISMS ; STRATEGIES ; CHEMOTHERAPY ; DOXORUBICIN ; CARCINOMA ; REVERSAL
英文摘要:

Multidrug resistance (MDR) is a major impediment to the effective chemotherapy of many human malignancies, and novel MDR reversal agents are desirable for combination therapy to reduce MDR, enhance anti-tumor activity and reduce side effects. Overexpression of P-glycoprotein (P-gp) is the most prevalent cause of MDR in cancer tissues, and resistance to apoptosis is a common characteristic for the multidrug resistant cancer cells. Our group has synthesized a novel potent anti-tumor indirubin derivative, PHII-7. In this study, MCF-7/ADR cells, an adriamycin (ADR)-selected human breast tumor cell line with the MDR phenotype, were used to investigate the anticancer properties of this novel indirubin derivative. Cytotoxicity and apoptosis assays showed that PHII-7 significantly inhibited cell growth, induced apoptosis, potentiated ADR cytotoxicity and restored chemotherapy sensitivity in the MDR cancer cells. Further studies indicated that by down-regulation of P-gp expression, PHII-7 partially inhibited P-gp efflux pump function and increased intracellular accumulation of Rhodamine 123, a P-gp substrate. These results provide a biochemical basis for possible clinical application of PHII-7 alone or in combination with conventional antineoplastic agents in the treatment MDR tumors. (C) 2011 Elsevier B.V. All rights reserved.

语种: 英语
所属项目编号: 30873091 ; 30971291
项目资助者: National Natural Science Foundation of China
WOS记录号: WOS:000296989500006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54930
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Chinese Acad Med Sci, Dept Pharmacol, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
2.Chinese Acad Med Sci, Hosp Blood Dis, Tianjin 300020, Peoples R China
3.Peking Union Med Coll, Tianjin 300020, Peoples R China
4.Shanxi Med Univ, Dept Pharmacol, Taiyuan 030001, Shanxi, Peoples R China
5.Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
6.Beijing Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100036, Peoples R China

Recommended Citation:
Shi, Ruizan,Li, Wei,Zhang, Xiuli,et al. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells[J]. EUROPEAN JOURNAL OF PHARMACOLOGY,2011,669(1-3):38-44.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Shi, Ruizan]'s Articles
[Li, Wei]'s Articles
[Zhang, Xiuli]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Shi, Ruizan]‘s Articles
[Li, Wei]‘s Articles
[Zhang, Xiuli]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace